UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI

• Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Ax…

Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary

• Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthrit…

EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts 1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC 2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC @RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc

Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg

• https://twitter.com/meralelramahimd/status/1324768543733407744

Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0

• Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Art…

What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93

• https://twitter.com/mdwarrington/status/1324743310758563840

Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J